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Background: Maximal oxygen uptake is impaired in end-stage renal disease (ESRD), reducing
quality of life and longevity. Whilst determinants of maximal exercise intolerance are well
defined, little is known of limitation during sub-maximal constant load exercise. By comparing
individuals with ESRD and healthy controls, the aim of this exploratory study was to
characterise mechanisms of exercise intolerance in ESRD participants by assessing
cardiopulmonary physiology at rest and during exercise.
Methods: Resting spirometry and echocardiography were performed in 20 dialysis-dependent
ESRD participants (age: 59±12; 14 male) and 20 healthy age and gender matched controls. 
Exercise tolerance was assessed with ventilatory gas exchange and central hemodynamics
during a maximal cardiopulmonary exercise test (CPEX) and 30 minutes of sub-maximal
constant load exercise (CLEX).
Results: Left ventricular mass (292±102 vs. 185±83 g; p = 0.01) and filling pressure (E/e’:
6.48±3.57 vs. 12.09±6.50 m/s; p = 0.02) were higher in ESRD participants; forced vital capacity
(3.44 ± 1 vs. 4.29 ± 0.95 L/min; p = 0.03) and peak VO2 (13.3±2.7 vs. 24.6±7.3 ml.kg-1.min-1; p
< 0.001) were lower. During CLEX, the relative increase in (a-v) O2 difference (13 ± 18 vs. 74 ±
18%) and heart rate (32±18 vs. 75±29%) were less in ESRD participants despite exercise being
performed at a higher percentage of maximum VE (48±3 vs 39±3%) and HR (82±2 vs. 64±2%).
Conclusion: Ventilatory and chronotropic incompetence contribute to exercise intolerance in
individuals with ESRD. Both are potential targets for medical and lifestyle interventions.
Key words: NICOM, non-invasive cardiac output monitor; VE, minute ventilation; (a-v) O2 








         
      
     
        
        
  
        
        
       
          
        
          
   
 
        
        
       
        
        
         
       
        
      
           
       
            
           
        
        
 
Introduction
Compared to the general population, maximal oxygen uptake (VO2 peak) is reduced by as
much as 50% in end-stage renal disease (ESRD) (1). This exercise intolerance, indicating
subclinical and pathological cardiopulmonary impairment, negatively affects activities of daily 
living and contributes to increased all-cause mortality (1). Our understanding of exercise
intolerance in ESRD comes primarily from studies performed with maximal cardiopulmonary
exercise testing (CPEX) (2, 3). Whilst maximal exercise testing provides useful information,
limitations to activities of daily living may be better understood by observing the physiological 
response to sustained sub-maximal exercise. This kind of exercise more accurately reflects
guidelines for physical activity and health, and many common recreational, leisure and
domestic activities such as housework and walking. No study to date has comprehensively
evaluated the physiological response to sustained, sub-maximal exercise in people with ESRD. 
Such studies may help identify additional mechanisms of exercise intolerance in ESRD and
inform interventions to attenuate their effects.
In a healthy cardiovascular system, exercise is accompanied by a sympathetically driven
increase in ventilation and heart rate, facilitating greater O2/CO2 exchange and cardiac 
output. Combined vasodilation to active tissue (cardiac, pulmonary, cerebral and skeletal
muscle) and vasoconstriction to non-active tissue, aids venous return, further augmenting
cardiac output via increased left ventricular filling pressures (4). This combined response
facilitates oxygen delivery during exercise, enabling mechanical work via aerobic means (5).
In people with ESRD, limitations to cardiac output and ventilatory and cellular gas exchange
include, but are not limited to, cardiomyopathy, anaemia, systemic inflammation,
pulmonary/vascular hypertension, hypervolemia, and electrolyte imbalances (6). The effects 
of this pathology are evident during the assessment of maximal exercise capacity. However,
comprehensive investigation of cardiovascular, metabolic and ventilatory function during
exercise has not been undertaken in individuals with ESRD, particularly in the context of 
sustained constant load exercise (CLEX). In the few available studies comparing healthy
controls with small ESRD cohorts, impaired oxygen uptake (VO2), heart rate, catecholamine





       
        
            
       
      
          
         
         
      
 
      
       
         
    
 
 
         
        




         
     
      
       
    
          
       
       
          
Cardio-pulmonary exercise testing can identify multi-system physiological limitation and, as
such, is an important diagnostic and prognostic tool in many pathologies. In ESRD, assessment
of oxygen uptake at peak exercise and at the ventilatory anaerobic threshold is predictive of
survival (2). However, maximal exercise performance is often symptom limited and hindered
by patient motivation (9). Alternatively, sub-maximal exercise testing may provide unique
insights into exercise intolerance in ESRD. The intensity and sustained nature of this exercise
better represents many activities of daily living and is less dependent on motivation. Sub-
maximal constant load exercise may aid our understanding of physiological limitation in ESRD, 
previously not identified by maximal testing. 
By studying the exercise response during sub-maximal constant load and maximal exercise in
both healthy individuals and those with ESRD, the aim of this comparative physiology study
was to explore key limitations and mechanisms of exercise intolerance in ESRD patients
undergoing regular haemodialysis.
Methods
Informed consent was obtained from all participants and the study was approved by the U.K. 
Health Research Ethics Committee (17/LO/0368) and registered with Clinicaltrials.gov 
(NCT03064555). All procedures were conducted in accordance with the Declaration of
Helsinki. 
Study procedures
Untrained ESRD patients undergoing regular haemodialysis were recruited from University
Hospital Coventry and Warwickshire NHS Trust. Simultaneously, age and gender matched
healthy controls were recruited from a Coventry University register of trial volunteers. 
Participants from both groups underwent; 1) resting echocardiography, spirometry and
brachial artery oscillometry; 2) a maximal cardiopulmonary exercise test (CPEX); and 3) a sub-
maximal constant load exercise test (CLEX). To reduce the potential effects of fluid overload
and hemodynamic changes resulting from hemodialysis treatment in the ESRD participants, 
testing was scheduled for the first non-dialysis day, 12 hours after the previous treatment. 





     
       




          
          
    
       
      
     
 
    
     
           
     
 
 
      
      
       
       
            
     
     
   
      
   
 
performance. Measures during CPEX and CLEX included ventilatory gas exchange, heart rate
(HR) and blood pressure (BP). Additionally, data on central hemodynamics (stroke volume,
cardiac output, total peripheral resistance, mean arterial pressure) were collected during
CLEX. 
Participants
Untrained adults with ESRD, able to perform CPEX and CLEX, undergoing three times weekly
hemodialysis treatment for greater than three months, were invited to take part. Exclusion
criteria included evidence of clinically significant valvular insufficiency or dysrhythmia, intra­
dialytic blood pressure >180 systolic or >95 diastolic, >3 litres fluid accumulation between
hemodialysis sessions, hemoglobin < 9.0 g/dL, ischemic cardiac event (<1 month), and
planned kidney transplant during the study.
Moderately active (<150 minutes moderate intensity exercise weekly) age and gender
matched healthy individuals were eligible for the comparative control group. Exclusion
criteria included disease or comorbidity which would prevent full participation in exercise
testing or likely elicit an abnormal cardiorespiratory response to exercise.
Echocardiogram 
Resting transthoracic echocardiography images were acquired and analyzed (Vivid IQ, Echo-
pack version 7.0, GE Medical Systems) by a clinical sonographer prior to CPEX testing, abiding
by American Society of Echocardiography guidelines (10). Left ventricular (LV) volumetric
parameters were assessed in 2-D and calculated using the Simpson’s bi-plane method. Left
ventricular mass was calculated at the end of diastole using the 2-D truncated ellipsoid
technique. In the apical four-chamber view, pulsed wave Doppler assessed the ratio of early 
to late mitral inflow velocity (E/a) and E-wave deceleration time. Tissue Doppler imaging was
used to quantify peak septal and lateral mitral annuli velocities. Subsequently, the ratio of 
peak early mitral inflow velocity to mean peak early annuli velocity (E/e’) was reported as a






         
       
       
        
            
      
 
     
      
     
            
   
 
  
     
       
           
     
        
     
        
            
      
        
         
            
       
 
Spirometry
Resting respiratory function was assessed with spirometry. Participants were asked to
breathe normally through a respiratory flow sensor (Ergospirometer, Ergostik, Geratherm
Respiratory, Bad Kissingen, Germany). After assessment of tidal flow, each participant
performed one maximal inhalation and exhalation. On verification of quality, data were
analyzed to provide outputs of forced vital capacity (FVC), forced expiratory volume in one
second (FEV1) and the FEV1/FVC ratio.
Brachial artery oscillometry 
To determine arterial stiffness, brachial artery oscillometry (Mobil-O-Graph 24h PWA
Monitor, I.E.M. GmbH, Stolberg, Germany) was performed. A cuff was automatically inflated
and deflated around the participants’ upper (non-fistula) arm, and pulse wave velocity and
augmentation index were subsequently calculated.
Noninvasive cardiac output monitor
Throughout CLEX, noninvasive cardiac output monitor (NICOM) bioreactance (Cheetah
Medical, Wilmington, Delaware, USA) was used to evaluate central hemodynamics. Four dual
sensor electrodes, placed superior to the iliac crest and scapula, measured the relative phase
shift of oscillating current traversing the thorax. Each electrode emitted a high-frequency
current, averaged after digital processing for 30 seconds. The signal processing unit
determines the relative phase shift (∆ϕ) between the input signal, relative to the output
signal. ∆ϕ was calculated relative to changes in blood flow through the aorta, allowing
estimation of stroke volume with the equation: SV = C ˙ VET ˙dϕ/dtmax1. C is a constant of
proportionality and VET is ventricular ejection time determined with ECG as the time between
aortic valve opening and closure. dϕ/dtmax indicates the relative bioreactance phase shift from
the injected and returning current after traversing the thorax. Cardiac output (CO) was
subsequently calculated as the product of stroke volume (SV) and heart rate (HR). In previous





   
     
      
      
       
           
        
      
         
        
      
         
       
            
 
     
        
    
      
        
             
      
          
         
          
    
 
  
            
       
   
Cardiopulmonary exercise test
Cardiopulmonary exercise testing was conducted using an electronically braked cycle
ergometer (Ergoline, Love medical, Manchester) with a ramped protocol until exhaustion
(13). Sensations associated with the test (e.g. leg fatigue, breathlessness) were explained to
participants to limit premature test termination. Participants rested for three minutes to
acquire baseline O2 saturation, blood pressure and HR, then continued with three minutes
unloaded cycling at 50rpm. Workload was then increased (5-20 W/min) until exhaustion, with
starting load was determined by physical activity history. Electrocardiogram was recorded
throughout and BP at two-minute intervals. VO2 peak was identified as the mean O2 uptake 
during the final 20 seconds of exercise. Oxygen uptake at the anaerobic threshold (VO2AT)
was derived via the V-Slope method in conjunction with ventilatory equivalents (13). 
Predicted VO2 peak was determined via the Wasserman and Hansen equation (14). The
oxygen uptake efficiency slope (OUES), was calculated as the slope of the regression line
between VO2 and the logarithmic transformation of VE, from rest to VO2 peak.
Constant load exercise test (CLEX)
Constant load exercise was performed on an electronically braked cycle ergometer (lower
body bi-directional ergometer, Hudson Fitness, Dallas, Texas) in the semi-recumbent position. 
Cardiovascular hemodynamics and ventilatory gas exchange were monitored throughout. 
Participants started with a five-minute warm-up, after which exercise commenced at a
workload (watts) equivalent to 90% VO2AT, determined from CPEX, for a duration of 30
minutes. Calculation of systemic arterial venous O2 difference was performed indirectly with
the Fick equation (VO2 = CO x [Ca-Cv]; rearranged to: VO2/CO= [Ca-Cv]), where Ca denotes
arterial O2 content, and Cv denotes venous O2 content. On completion of the protocol, all
participants underwent an unloaded three-minute cool down period at 50 rpm. An additional
two-minute resting period was monitored.
Statistical analysis
Due to the exploratory nature of the study, an a priori power calculation was not performed.
Data were analyzed with the statistical software package SPSS (Version 21, SPSS Inc., Chicago, 





          
      
   
     
           
        
 
 
      
               
          
        
           
  
 
    
        
        
         
     
        
      
    
    
    
    
 
  
   
      
       
       
     
    
      
    
     
     
       
variables were analyzed between groups using an independent samples t-test for each
variable. The analysis of gas exchange and cardiovascular responses during CLEX was carried
out using a two-way between subjects general linear model to identify differences between
groups. Where appropriate, post-hoc analysis identified significance between measurements 
at each time point between groups. All data were expressed as mean ± SD. p < 0.05 indicated
statistical significance and p = 0.000 was corrected to p < 0.001 (15).
Results
From May 2017 to December 2018, 71 ESRD patients were screened. Twenty-nine were
eligible and 20 agreed to participate. Of the 20 healthy controls screened, all agreed to take
part. All ESRD and healthy participants completed both CPEX and CLEX. One ESRD participant
became fatigued during CLEX, briefly stopping twice to recover. No other participants in either
group experienced any symptoms. Groups were well matched for age, gender and body mass
index (table 1).
Table 1: Participant characteristics.
Participant characteristics Healthy (n = 20) ESRD (n = 20) P
Age (yrs) 59 ± 10 59 ± 12 0.83
Weight (kg) 77 ± 16 74 ± 15 0.51
Height (cm) 175 ± 9 171 ± 10 0.31
BMI (kg/m2) 25 ± 4 25 ± 4 0.92
Gender, n (male/female) 14/6 14/6 0.84
Ethnicity
Black 1 5 N/a
Caucasian 19 13 N/a
Asian 0 2 N/a
Smoking status (n), 0/0/20 3/3/14 N/a 
(current/former/never)
Hemodialysis vintage (months) N/a 41 ± 39 N/a
Central venous catheter (n, %) N/a 2 (10) N/a
Arterial venous fistula (n, %) N/a 18 (90) N/a
Comorbidities (n, %)
Diabetes 0 4 (20) N/a
Hypertension 6 (30) 12 (60) N/a
Cerebral vascular disease 0 3 (15) N/a
Coronary artery disease 0 7 (35) N/a
Peripheral vascular disease 0 1 (5) N/a





    
     
     
    
    
     
    
    
    
    
    
     
     
      
    
          
 
   
           
             
         
      
 
      
       
         
        
     
       
         
     
         
           
        
       
    
      
      
       
    
       
Carcinoma 0 3 (15) N/a
Asthma 0 0 N/a
COPD 0 1 (5) N/a
Hyperparathyroidism 0 5 (25) N/a
Medication (n, %)
Anti-hypertensives 5 (25) 16 (80) N/a
Antiplatelet 1 (5) 3 (15) N/a
Anticoagulants 0 8 (40) N/a
Statins 1 (5) 8 (40) N/a
Diuretics 0 5 (25) N/a
Anti-Arrhythmic 0 1 (5) N/a
Beta-blockers 0 11 (55) N/a
Hypoglycemic agents 0 5 (5) N/a
ESRD, end-stage renal disease; BMI, body mass index; eGFR, estimated glomerular filtration
rate; COPD, chronic obstructive pulmonary disease; CKD, chronic kidney disease; ACE,
angiotensin converting enzyme. Values expressed as absolute or mean ± SD.
Resting cardiopulmonary and arterial function
Left ventricular mass, end diastolic volume (LVEDV), ! velocity and mean E/e’ were higher in
ESRD compared to healthy controls (table 2). FVC and FVC1 were lower in ESRD but not
indicative of restrictive or obstructive pulmonary disease. There was no difference between
groups in augmentation index or pulse wave velocity.
Table 2: Resting cardiac, respiratory and vascular parameters
Echocardiogram Healthy (n = 20) ESRD (n = 20) P
LVEF (%) 64 ± 6 63 ± 11 0.71
Stroke volume (ml) 62 ± 26 60 ± 20 0.81
LV mass (g) 185 ± 83 292 ± 102 0.01*
LV mass/BSA (g/m2) 69 ± 51 148 ± 60 < 0.001*
LAESV (ml) 58 ± 23 69 ± 37 0.33
LVEDV (ml) 103 ± 40 117 ± 59 0.002*
LVEDV/BSA (g/m2) 41 ± 25 62 ± 26 0.24
LVESV (ml) 39 ± 21 52 ± 36 0.39
LVESV/BSA 16 ± 11 24 ± 17 0.37
E-velocity (m/s) 0.77 ± 0.23 0.85 ± 0.31 0.52
Deceleration time (m/s) 226 ± 36 213 ± 40 0.43
A-velocity (m/s) 0.57 ± 0.14 0.90 ± 0.30 0.004*
E/a (m/s) 1.35 ± 0.61 1.08 ± 0.54 0.26
Mean E/e’ (m/s) 6.48 ± 3.57 12.09 ± 6.50 0.02*
Spirometry




         
       
        
          
     
      
 
     
       
     
   
          
 
 
           
         
     
 
    
        
    
       
      
      
      
        
        
       
        
        
    
        
     
       
       
      
      
        
        
       
% of predicted 108 ± 24 86 ± 23 0.02*
FEV1 (L/sec) 3.22 ± 0.68 2.30 ± 0.88 0.02*
% of predicted 105 ± 21 81 ± 24 0.01*
FEV1/FVC ratio 78 ± 5 75 ± 10 0.42
Brachial artery oscillometry  
Augmentation index 23.14 ± 10.34 28.75 ± 26.06 0.38
Pulse wave velocity 8.6 ± 1.6 9.2 ± 1.6 0.19
(n/m)
ESRD, end-stage renal disease; LVEF, left ventricular ejection fraction; LV, left ventricular; BSA,
body surface area; LAESV, left atrial end-systolic volume; LVEDV, left ventricular end-diastolic
volume; LVESV, left ventricular end-systolic volume; FVC, forced vital capacity; FEV1, forced
expiratory volume in one second. Values expressed as mean ± SD. *p < 0.05 between groups.
Cardio-pulmonary exercise test 
At rest, breathing reserve was lower, and HR was higher in the ESRD group (table 3). At the
anaerobic threshold and at peak exercise, VO2, VCO2, ventilation (VE), O2 pulse, HR and work
rate were lower in the ESRD group. 
Table 3: Cardiopulmonary exercise test parameters.
CPEX parameters Healthy (n = 20) ESRD (n = 20) P value
Rest
VO2 (ml.kg-1.min-1) 3.2 ± 0.9 3.3 ± 1.0 0.70
VCO2 (ml.kg-1.min-1) 2.7 ± 7.3 3.1 ± 1.1 0.74
RER 0.88 ± 0.07 0.89 ± 0.10 0.87
VE (L/min) 9.6 ± 2.8 9.1 ± 2.6 0.59
O2 pulse (VO2/HR) 4.1 ± 1.2 3.3 ± 0.9 0.11
BR (%) 93 ± 3 90 ± 5 0.03*
RR (breaths/min) 16 ± 4 17 ± 5 0.61
PET CO2 34 ± 3 37 ± 4 0.06*
HR (bpm) 64 ± 11 80 ± 15 0.002*
SBP (mmHg) 132 ± 18 138 ± 40 0.64
DBP (mmHg) 83 ± 13 81 ± 36 0.86
Anaerobic threshold
VO2 (ml.kg-1.min-1) 17.42 ± 7.00 9.15 ± 2.58 < 0.001*
VCO2 (ml.kg-1.min-1) 17.56 ± 7.06 9.36 ± 2.82 < 0.001*
RER 1.00 ± 0.07 1.00 ± 0.06 0.76
VE (L/min) 38.9 ± 18.4 23.1 ± 6.8 0.002*
O2 pulse (VO2/HR) 12.5 ± 4.3 7.4 ± 1.9 0.001*
BR (%) 71 ± 13 74 ± 10 0.37





        
      
    
        
       
    
        
           
       
      
      
        
        
      
        
    
    
        
       
       
 
 
     
         
    
  
      
            
      
 
    
          
            
         
                    
      
 
         
               
PET CO2 42 ± 4 39 ± 4 0.07*
HR (bpm) 111 ± 21 94 ± 11 0.003*
SBP (mmHg) 159 ± 23 146 ± 34 0.24
DBP (mmHg) 79 ± 18 81 ± 31 0.82
WR (watts) 109 ± 62 39 ± 14 < 0.001*
Peak
VO2 (ml.kg-1.min-1) 24.6 ± 7.3 13.3 ± 2.7 < 0.001*
% predicted VO2 90 ± 21% 47 ± 16% < 0.001*
VCO2 (ml.kg-1.min-1) 30.9 ± 7.1 15.00 ± 6.42 < 0.001*
RER 1.36 ± 0.20 1.26 ± 0.15 0.402
VE (L/min) 83.5 ± 18.1 45.3 ± 13.9 < 0.001*
O2 pulse (VO2/HR) 13.4 ± 4.3 8.9 ± 2.0 0.003*
BR (%) 42 ± 9 52 ± 19 0.10
RR (breaths/min) 34 ± 10 30.3 ± 7.4 0.27
PET CO2 36 ± 6 36 ± 4 0.90
HR (bpm) 149 ± 15 113 ± 17 < 0.001*
SBP (mmHg) 182 ± 31 168 ± 40 0.24
DBP (mmHg) 97 ± 22 84 ± 28 0.29
WR (watts) 173 ± 66 70 ± 17 < 0.001*
OUES (L/min/log L/min) 1839 ± 825 1074 ± 183 < 0.001*
ΔVO2/ΔWR slope 9.7 ± 1.4 9.2 ± 1.4 0.41
(ml/min/watt)
VE/VCO2 slope 33 ± 8 32 ± 5 0.46
CPEX, cardiopulmonary exercise test; ESRD, end-stage renal disease; RER, respiratory
exchange ratio; VE, minute ventilation; BR, breathing reserve; RR, respiratory rate; PETCO2, 
end tidal carbon dioxide tension; HR, heart rate; SBP, systolic blood pressure; DBP, diastolic
blood pressure; WR, work rate; OUES, oxygen uptake efficiency slope. Values expressed as
mean ± SD. *p < 0.05 between groups.
Constant load exercise test
Minute ventilation: Throughout exercise, mean VE was higher in healthy controls compared
to ESRD (31.6 ± 2.0 vs. 20.0 ± 1.7 L/min, p < 0.001) (figure 1). When VE was expressed relative 
to peak VE attained during CPEX, the ESRD group ventilated at a higher percentage of peak
(48 ± 3 vs. 39 ± 3%, p = 0.04). The relative increase in VE from rest was less in ESRD compared
to healthy controls (124 ± 25 vs. 209 ± 26%, p = 0.02).
Heart rate: Mean HR was higher throughout exercise for healthy controls compared to ESRD





            
           























the ESRD group had a smaller relative increase in HR from rest than healthy controls (26 ± 5 
vs. 59 ± 5%, p < 0.001). Additionally, the ESRD group exercised at a higher percentage of HR 
















































































































































































































       
            
          
       
        
 
       
             
           
 
        
              
                  
 
 
         
                
           














Figure 1: ESRD, End-stage renal disease; VE, minute ventilation; HR, heart rate. VE (A), % of 
peak VE (B), % change in VE from rest to steady state (C), HR (D), % of peak HR (E) % change
in HR from rest to steady state (F) during constant load exercise test in healthy and end-stage
renal disease participants. -5 start of warm up. Zero minutes indicates start of CLEX. 30-33: 3­
minute cool down. Values expressed as mean ± SD. *p < 0.05 between groups.
Arterial venous O2 difference: There was no difference between groups in absolute (a-v) O2 
difference (figure 2). The relative change in (a-v) O2 difference from rest was greater in healthy
controls than in ESRD (74 ± 18 vs. 13 ± 18%, p = 0.03).
Stroke volume: Mean SV was greater during exercise for healthy controls compared to ESRD, 
but not significantly (124 ± 9 vs 111 ± 8 ml, p = 0.27) (figure 2). In contrast, the relative increase
in SV from rest was greater in the ESRD group, again not significantly (50 ± 10 vs. 25 ± 11, p =
0.10).
Cardiac output: Mean CO was greater throughout exercise for healthy controls compared to
ESRD (12.2 ± 0.8 vs 10.1 ± 0.7 L/min, p = 0.07), but did not reach statistical significance. There
was no difference between the two groups in the relative increase from rest (104 ± 17 vs. 94 
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Figure 2: ESRD, End-stage renal disease; (a-v) O2 difference, arterial venous O2 difference; SV,
stroke volume, CO, cardiac output. (a-v) O2 difference (A), % change in (a-v) O2 difference (B), 
SV (C), % change in SV (D), CO (E), % change in CO (F) during CLEX between healthy and ESRD
groups. -5 start of warm up. Zero minutes indicates start of CLEX. 30-33: 3-minute cool down. 
33-35: 2-minute rest period. Values expressed as mean ± SD. *p < 0.05 between groups.
Ventilatory and hemodynamic parameters: Absolute, but not relative, VO2 was lower
throughout exercise in the ESRD group compared to healthy controls (table 4). Similarly,
absolute, but not relative VCO2 was higher. Mean respiratory exchange ratio was the same
for both groups. Mean SBP was higher in the ESRD group compared to healthy controls whilst
mean DBP and MAP were the same. TPR was higher in the ESRD group.
Table 4: Mean ventilatory and hemodynamic parameters during CLEX
Healthy (n = 20) ESRD (n = 20) P value
VO2 (ml.kg-1.min-1) 13.5 ± 3.7 8.1 ± 1.8 <0.001*
% of VO2 peak 51.7 ± 14.1 62.1 ± 21.8 0.10
VCO2 (ml.kg-1.min-1) 11.7 ± 3.2 7.6 ± 2.42 <0.001*
% of VCO2 peak 39.3 ± 15.8 40.6 ± 12.7 0.80
RER 1.0 ± 0.1 1.0 ± 0.1 0.74
SBP (mmHg) 142.2 ± 16.9 158.0 ± 26.4 0.04*
DBP (mmHg) 86.2 ± 9.8 86.6 ± 18.9 0.93
MAP (mmHg) 105.0 ± 11.9 110.2 ± 20.2 0.34
TPR (mmHg) 828.9 ± 150.5 1011 ± 306.8 0.03*
Data as mean ± SD. -5 start of warm up. RER, respiratory exchange ratio; SBP, systolic blood
pressure; DBP, diastolic blood pressure; MAP, mean arterial pressure; TPR, total peripheral






           
      
           
          
      
      
   
  
    
         
         
         
            
          
        
         
           
         
      
      
       
      
      
 
 
             
                
          
           
            
Discussion
By directly comparing the physiology of individuals with ESRD and age and gender-matched
healthy controls, we identified previously unreported limitations during maximal and sub-
maximal exercise. Most notably, in addition to the well-documented reduction in VO2 peak in
ESRD, we observed a marked impairment in heart rate, ventilation and oxygen extraction
during sub-maximal constant load exercise. Our data suggest dysregulated cardiovascular,
pulmonary and skeletal muscle physiology during sub-maximal and maximal exercise in
patients with ESRD.
Resting physiological measures
Lung function was reduced at rest in ESRD participants, suggestive of chronic deconditioning.
Although not extensively documented, these data add to the limited existing literature by
directly comparing ESRD with age and gender-matched healthy controls (16, 17). Restrictive
lung dysfunction is present in a third of individuals with ESRD (18), although was not evident
in our data. Nevertheless, our findings indicate that ESRD results in decreased pulmonary
function, possibly explained by physical deconditioning alone, or in combination with
impaired ventilatory mechanics (19, 20). Echocardiography in our study indicated that LV
mass and E/e’ (LV filling pressure) were higher in the ESRD group. In combination, these
findings suggest evolving LV hypertrophy and diastolic dysfunction in ESRD, which are well
known predictors of exercise intolerance (21-23). Arterial compliance, assessed with
augmentation index and pulse wave velocity, was similar between groups as previously
reported between ESRD participants and hypertensive controls (24). Despite our comparator
group consisting predominantly of normotensive controls, six participants were diagnosed
with hypertension, which may explain this anomaly.
Cardiopulmonary exercise test
Reduced VO2 peak is well documented in ESRD and is strongly predictive of mortality (1, 3,
24). In our study, VO2 peak in the ESRD group was only 54% of that achieved by healthy
controls. We can be confident that these values represent impaired function, as opposed to
poor compliance with the maximal testing protocol, as indicated by an RER exceeding 1.25 in





         
     
           
           
            
        
      
      
 
         
         
             
             
         
         
       
         
    
       
             
       
          
     
   
 
    
          
          
          
       
         
   
observational trials in ESRD (VO2peak: < 17.5 ml.kg-1.min-1) (25, 26). Substantially decreased
O2 uptake efficiency (OUES) was also apparent in ESRD participants. Collectively these data 
confirm that our ESRD population were severely deconditioned, consistent with an advanced
ESRD phenotype. Minute ventilation in ESRD participants was also only half that achieved by
healthy controls during maximal exercise. In a previous study, this difference was not
apparent in a cohort of CKD 3-4 patients (25), suggesting our finding may be unique to ESRD.
These data indicate decreased respiratory reserve, likely due to both reduced respiratory
drive and lower tidal volume during exercise, compared to healthy controls. 
Below the anaerobic threshold, HR was higher in the ESRD group. Despite this, at VO2 peak,
HR max was reduced in ESRD participants, as has been previously reported (24, 25). Whilst
the effect of beta-blockade in our ESRD group should be acknowledged, it is likely this was
minimal given that only half of the ESRD group were prescribed beta-blockers, and resting HR
was higher in the ESRD group. This suggests the difference between groups was not 
pharmacologically mediated, rather it reflects reduced HR reserve and chronotropic
incompetence, as is common in cardiovascular disease, hypertension and heart failure (27).
Chronotropic incompetence in ESRD is thought to be due to decreased catecholamine
sensitivity resulting from impaired renal clearance of catecholamines and increased
circulating angiotensin II (8, 28). Decreased O2 pulse, a surrogate marker of stroke volume, 
was also evident at peak exercise and at the anerobic threshold in our study, potentially
indicating impaired myocardial function during periods of increased metabolic demand.
Therefore, it appears that cardiac output is impaired in ESRD by numerous mechanisms
including chronotropic incompetence and diastolic dysfunction, thus limiting exercise
capacity.
Constant load exercise test
In absolute terms, VE was significantly lower throughout CLEX in our ESRD cohort compared
to healthy controls. The relative increase from rest was also lower but the ESRD group
exercised at a higher percentage of VE max achieved during CPEX. These data suggest an
inability to augment ventilation in response to exercise. This phenomenon has been described
previously during exercise in small exploratory trials (6, 17). The precise mechanisms





           
         
        
       
       
         
             
         
         
 
       
     
          
          
        
         
        
  
 
         
         
         
     
         
           
      
         
   
 
            
         
         
cardiomyopathy and decreased expression of pulmonary aquaporin five channels, risk fluid
retention and pulmonary oedema in ESRD, which may limit mechanical ventilation through
small airway dysfunction and pulmonary congestion (29). Decreased VE has also been
documented during haemodialysis as a result of acute alkalosis from bicarbonate-based
dialysate, which may persist during the post-dialytic period (30, 31). Acute alkalosis during
the inter-dialytic period therefore may explain the abnormal VE response to exercise in our
study, although data are not available to confirm this. Irrespective of the cause, our data and
previous findings suggest that impaired pulmonary function greatly contributes to exercise
intolerance in ESRD possibly as a result of ventilatory and gas exchange abnormalities. 
Despite a significant difference in absolute VO2 during CLEX between healthy controls and
ESRD participants, there was no difference when this was expressed as a percentage of VO2 
peak achieved during CPEX i.e. CLEX was performed at the same relative intensity in both
groups. However, a smaller percentage change in (a-v) O2 difference was evident for the ESRD
group, suggestive of impaired O2 extraction. Subsequently, our data support reduced muscle
energetic efficiency and O2 extraction in ESRD. This decreased O2 efficiency may contribute
to exercise intolerance, limiting activities of daily living, and impacting on quality of life in
ESRD (6, 32). 
An attenuated HR response was evident during CLEX in our ESRD cohort compared to healthy 
controls. We observed a higher percentage of HR max, and a lower relative increase in HR in
the ESRD cohort. Therefore, despite ESRD participants performing exercise at a higher relative
HR, this represented a smaller relative increase from resting levels than in healthy controls.
Chronotropic incompetence has been previously documented during sub-maximal exercise in
ESRD participants, even in the presence of higher levels of circulating noradrenaline and
adrenaline (8). This suggests that there may be a chronically decreased sensitivity to 
sympathetic hormones in ESRD, resulting in an inability to augment HR in response to
increased metabolic demand. 
In conjunction with a smaller relative increase HR in our ESRD cohort, the relative change in
SV appeared to be greater, albeit not statistically significant. Cardiac output did not differ 





           
            
            
       
      
         
      
          
   
 
          
        
        
      
        
         
        
      
 
 
             
   
         
            
       
         
        
     
 
depend on augmented SV in the absence of an increase in HR. This may be problematic in
those with coexisting LV dysfunction evidenced in the current ESRD cohort by decreased O2 
pulse, and increased LV mass and diastolic filling pressures. When a rapid increase in CO is
required, the inability to quickly increase either HR or SV will result in breathlessness, fatigue
and exercise intolerance. These maladaptations, specifically decreased HR reserve,
autonomic dysfunction, SV dependency and LV dysfunction, may explain reduced VO2 peak
during CPEX, and altered physiology during CLEX. These data improve our understanding of
exercise intolerance, reduced quality of life and an inability to respond to hemodynamic 
challenges in ESRD.
Prior to exercise, blood pressure and total peripheral resistance were similar between groups. 
In contrast, during sub-maximal exercise, mean values for SBP and TPR were greater in the
ESRD group. These data likely suggest endothelial dysfunction in our ESRD cohort during
susatined sub-maximal exercise (6). Systemic vascular calcification and atherosclerosis likely
contribute to this phenomenon. An inability to sufficiently induce arterial vasodilation likely 
further impedes O2 utilisation at the tissue level, potentially limiting oxygen uptake in
conjunction with cardiopulmonary dysregulation. These data support previous findings
whereby arterial stiffness predicted reduced VO2 peak (33, 34).
Limitations
It is likely that both the healthy and ESRD cohorts were too small to detect changes in this
exploratory study for all the variables investigated, specifically haemodynamics during CLEX
(CO and SV), which did not reach significance despite apparent differences. In addition, the
ethnicity of our ESRD group differed from our predominantly Caucasian healthy controls but
there is no evidence to support an effect of ethnicity on cardiopulmonary responses to
exercise that would explain the current findings. We determined (a-v) O2 difference indirectly
using CO and VO2, and used brachial artery oscillometry for the assessment of arterial stiffness






       
        
       
    
         
      
 
  
          
          
            
 
 
        
       
        
 
          
 
          
     
 
       
      
   
 
       
        
         
Conclusion
Maximal oxygen uptake was decreased in ESRD participants compared to healthy controls. 
Cardiovascular, pulmonary and skeletal muscle impairment was evident at rest and during
maximal and sub-maximal exercise. Our exploratory study identified potential causes of
exercise intolerance in ESRD, including compromised ventilatory function, chronotropic
incompetence and impaired muscle O2 extraction. These data provide new insights into
exercise intolerance in ESRD and highlight potential therapeutic targets.
Author contributions
G. M., S. M. and E. J. H. designed the study; S. M. and K. C. was responsible for data collection;
S. M. was responsible for data analysis; S. M. and G. M. drafted the manuscript; S. M., G. M.,
K. C., E. J. H., D. R., and N. K. revised the manuscript, and all authors approved the final version. 
Acknowledgements
We would like to thank Dr Danish Ali for supervision of cardiopulmonary exercise testing. Also,
the renal research department and renal nurses of University Hospital Coventry and
Warwickshire NHS trust for their support in completing this study.
Conflicts of interest: The authors declare that there is no conflict of interest.
Disclosures: Results presented in this paper have not been published previously in whole or
part, except in abstract format. 
Clinical trial registration: Project title: acute physiological responses to exercise in end-stage
renal disease (PRECISE). U.K. Health Research Ethics Committee (17/LO/0368); registered
with Clinicaltrials.gov (NCT03064555). https://clinicaltrials.gov/ct2/show/NCT03064555. 
Funding: The project was co-funded by Coventry University and University Hospital Coventry
and Warwickshire NHS trust via a PhD studentship for S.M. This research received no specific





      
  
 
         
   
    
     
 
         
   
 
    
   
   
      
         
       
    
      
 
      
    
    
   
       
    
       
    
       
     
      
       
    
Data Availability: The data underlying this article will be shared on reasonable request to
the corresponding author.
References
1. Ting SM, Iqbal H, Kanji H, Hamborg T, Aldridge N, Krishnan N, et al. Functional
cardiovascular reserve predicts survival pre-kidney and post-kidney transplantation. J Am
Soc Nephrol. 2014 Jan;25(1):187-95.
2. Segura-Orti E. Exercise in haemodyalisis patients: a literature systematic review. 
Nefrologia. 2010;30(2):236-46.
3. Lim K, Ting SMS, Hamborg T, McGregor G, Oxborough D, Tomkins C, et al. Cardiovascular
Functional Reserve Before and After Kidney Transplant. JAMA Cardiology. 2020 Feb
5,;5(4):420.
4. Rivera-Brown A, Frontera WR. Principles of Exercise Physiology: Responses to Acute 
Exercise and Long-Term Adaptations to Training. American Academy of Physical Medicine 
and Rehabilitation. 2012;4:797-804.
5. Vinet A, Nottin S, Lecoq AM, Obert P. Cardiovascular responses to progressive cycle 
exercise in healthy children and adults. Int J Sports Med. 2002 May;23(4):242-6.
6. Painter P. Determinants of exercise capacity in CKD patients treated with hemodialysis.
Adv Chronic Kidney Dis. 2009 Nov;16(6):437-48.
7. Castellino P, Bia M, DeFronzo RA. Metabolic response to exercise in dialysis patients.
Kidney Int. 1987 Dec;32(6):877-83.
8. Kettner A, Goldberg A, Hagberg J, Delmez J, Harter H. Cardiovascular and metabolic 
responses to submaximal exercise in hemodialysis patients. Kidney Int. 1984 Jul;26(1):66-71.
9. Kitzman DW, Groban L. Exercise intolerance
. Cardiol Clin. 2011 Aug 29;3:461-77.
10. Lang RM, Badano LP, Mor-Avi V, Afilalo J, Armstrong A, Ernande L, et al. 
Recommendations for cardiac chamber quantification by echocardiography in adults: an
update from the American Society of Echocardiography and the European Association of
Cardiovascular Imaging. Eur Heart J Cardiovasc Imaging. 2015 Mar;16(3):233-70.
11. Squara P, Denjean D, Estagnasie P, Brusset A, Dib JC, Dubois C. Noninvasive cardiac 
output monitoring (NICOM): a clinical validation. Intensive Care Med. 2007 Jul;33(7):1191-4.
12. Jones TW, Houghton D, Cassidy S, MacGowan GA, Trenell MI, Jakovljevic DG.
Bioreactance is a reliable method for estimating cardiac output at rest and during exercise. 





    
       
   
       
          
 
      
      
        
   
 
       
       
       
   
    
       
  
        
      
 
      
    
       
    
       
 
      
   
        
      
  
        
   
  
13. Balady GJ, Arena R, Sietsema K, Myers J, Coke L, Fletcher GF, et al. Clinician's Guide to 
cardiopulmonary exercise testing in adults: a scientific statement from the American Heart
Association. Circulation. 2010 Jul 13;122(2):191-225.
14. Arena R, Myers J, Abella J, Pinkstaff S, Brubaker P, Moore B, et al. Determining the 
preferred percent-predicted equation for peak oxygen consumption in patients with heart
failure. Circ Heart Fail. 2009 Mar;2(2):113-20.
15. Kinnear P, Gray C. SPSS 12 Made Simple. Taylor and Francis; 2006.
16. Fernandes AdO, Sens, Yvoty Alves Dos Santos, Xavier VB, Miorin LA, Alves, Vera Lúcia 
Dos Santos. Functional and Respiratory Capacity of Patients with Chronic Kidney Disease
Undergoing Cycle Ergometer Training during Hemodialysis Sessions: A Randomized Clinical 
Trial. International journal of nephrology. 2019;2019:7857824-7.
17. Faria RdS, Fernandes N, Lovisi JCM, Reboredo MdM, Marta, Murilo Sérgio de Moura,
Pinheiro BdV, et al. Pulmonary function and exercise tolerance are related to disease
severity in pre-dialytic patients with chronic kidney disease: a cross-sectional study. BMC
nephrology. 2013 Sep 4,;14(1):184.
18. Mukai H, Ming P, Lindholm B, Heimbürger O, Barany P, Stenvinkel P, et al. Lung 
Dysfunction and Mortality in Patients with Chronic Kidney Disease. Kidney and Blood
Pressure Research. 2018 Jun;43(2):522-35.
19. Campos L, Chan L, Zhang H, Deziel S, Vaughn C, Meyring-Wosten A, et al. Intradialytic
Hypoxemia in Chronic Hemodialysis Patients. Advances in Chronic Kidney Disease. 
2016;23(2):127.
20. Painter P. Determinants of exercise capacity in CKD patients treated with hemodialysis.
Adv Chronic Kidney Dis. 2009 Nov;16(6):437-48.
21. Wright J, Hutchison A. Cardiovascular disease in patients with chronic kidney disease. 
Vascular health and risk management. 2009;5:713-22.
22. Tuegel C, Bansal N. Heart failure in patients with kidney disease. Heart. 2017 
Dec;103(23):1848-53.
23. Grewal J, McCully RB, Kane GC, Lam C, Pellikka PA. Left Ventricular Function and Exercise 
Capacity. JAMA. 2009 Jan 21,;301(3):286-94.
24. Ting SM, Hamborg T, McGregor G, Oxborough D, Lim K, Koganti S, et al. Reduced
Cardiovascular Reserve in Chronic Kidney Failure: A Matched Cohort Study. Am J Kidney Dis.
2015 Aug;66(2):274-84.
25. Kirkman DL, Muth BJ, Stock JM, Townsend RR, Edwards DG. Cardiopulmonary exercise






    
    
 
       
    
      
   
      
    
 
    
       
      
  
        
       
    
      
   
     
      
       
  
       
       
    
          
 
   
26. Sietsema KE, Amato A, Adler SG, Brass EP. Exercise capacity as a predictor of survival 
among ambulatory patients with end-stage renal disease. Kidney International. 2004
Feb;65(2):719-24.
27. Routledge F, Campbell T, McFetridge-Durdle J, Bacon S. Improvements in heart rate 
variability with exercise therapy. Canadian Journal of Cardiology. 2010;26(6):303-12.
28. Kotanko P. Cause and Consequences of Sympathetic Hyperactivity in Chronic Kidney 
Disease. Blood Purification. 2005 Dec;24(1):95-9.
29. Husain-Syed F, McCullough PA, Birk H, Renker M, Brocca A, Seeger W, et al. Cardio­
Pulmonary-Renal Interactions: A Multidisciplinary Approach. J Am Coll Cardiol. 
2015;65(22):2433-48.
30. Tentori F, MD, Karaboyas A, MS, Robinson, Bruce M., MD, MS, Morgenstern H, PhD, 
Zhang J, MS, Sen A, PhD, et al. Association of Dialysate Bicarbonate Concentration With
Mortality in the Dialysis Outcomes and Practice Patterns Study (DOPPS). American Journal of
Kidney Diseases. 2013;62(4):738-46.
31. Meyring-Wösten A, Zhang H, Ye X, Fuertinger DH, Chan L, Kappel F, et al. Intradialytic
Hypoxemia and Clinical Outcomes in Patients on Hemodialysis. Clinical journal of the 
American Society of Nephrology : CJASN. 2016 Apr 7,;11(4):616-25.
32. Abbas Fadaii, Homayoun Koohi-Kamali, Bahador Bagheri, Fatemeh Hamidimanii, Bahar
Taherkhanchi. Prevalence of Pulmonary Hypertension in Patients Undergoing Hemodialysis.
Iranian Journal of Kidney Diseases. 2013 Jan 1,;7(1):60.
33. Wallin H, Asp AM, Wallquist C, Jansson E, Caidahl K, Hylander Rössner B, et al. Gradual 
reduction in exercise capacity in chronic kidney disease is associated with systemic oxygen
delivery factors. PloS one. 2018;13(12):e0209325.
34. Van Craenenbroeck AH, Van Craenenbroeck EM, Van Ackeren K, Hoymans VY, 
Verpooten GA, Vrints CJ, et al. Impaired vascular function contributes to exercise 
intolerance in chronic kidney disease. Nephrology, dialysis, transplantation : official 
publication of the European Dialysis and Transplant Association - European Renal
Association. 2016 Dec;31(12):2064-72.
24
 
